Latest News

Clinical Trials Roundup | 14 Aug 2026

Clinical Trials Roundup | 14 Aug 2026

Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...

read more

Latest News

Atacicept IgA Nephropathy: FDA Decision Due 7 July

Atacicept IgA Nephropathy: FDA Decision Due 7 July

Four days from now, the US Food and Drug Administration is due to hand down its atacicept IgA nephropathy decision, ruling on whether the experimental Vera Therapeutics drug becomes the first therapy to target both BAFF and APRIL in adults with the disease. The...

read more
Clinical Trials Roundup | 03 July 2026

Clinical Trials Roundup | 03 July 2026

Genmab and AbbVie's epcoritamab meets its primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, the FDA approves Orca Bio's Tregzi as the first regulatory T-cell therapy to reduce chronic graft-versus-host disease in blood...

read more
FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...

read more
What is the Metabolic Reset Diet – The Science

What is the Metabolic Reset Diet – The Science

The science, the promise, and the pitfalls The idea of a “metabolic reset” has gained traction across wellness media, social platforms, and weight management programmes. The premise is appealing: that metabolism can be “retrained” or “rebooted” through short-term...

read more
Functional Gut Clinic Launches GI Clinical Trials Division

Functional Gut Clinic Launches GI Clinical Trials Division

The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...

read more
Ergonomic Design Considerations in Health Tech

Ergonomic Design Considerations in Health Tech

Why comfort and fit are essential design considerations in medical devices In many industries, product design rarely accounts for the variability of user profiles, with a focus on the ‘average’ person.  Headphones or even glasses too often do not account for head size...

read more
EQT Targets Oxford Biomedica in Major Biotech Takeover Bid

EQT Targets Oxford Biomedica in Major Biotech Takeover Bid

Oxford Biomedica has officially confirmed it is in preliminary discussions with the Swedish private equity giant EQT regarding a potential cash takeover. The announcement follows significant market speculation and a sharp rise in the company’s share price on January...

read more
UK Boosts Clinical Trials With Faster, Agile Regulation

UK Boosts Clinical Trials With Faster, Agile Regulation

Press Release: Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation  The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more...

read more
GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...

read more
What is the Metabolic Reset Diet – The Science

What is the Metabolic Reset Diet – The Science

The science, the promise, and the pitfalls The idea of a “metabolic reset” has gained traction across wellness media, social platforms, and weight management programmes. The premise is appealing: that metabolism can be “retrained” or “rebooted” through short-term...

read more
Functional Gut Clinic Launches GI Clinical Trials Division

Functional Gut Clinic Launches GI Clinical Trials Division

The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...

read more
Ergonomic Design Considerations in Health Tech

Ergonomic Design Considerations in Health Tech

Why comfort and fit are essential design considerations in medical devices In many industries, product design rarely accounts for the variability of user profiles, with a focus on the ‘average’ person.  Headphones or even glasses too often do not account for head size...

read more
EQT Targets Oxford Biomedica in Major Biotech Takeover Bid

EQT Targets Oxford Biomedica in Major Biotech Takeover Bid

Oxford Biomedica has officially confirmed it is in preliminary discussions with the Swedish private equity giant EQT regarding a potential cash takeover. The announcement follows significant market speculation and a sharp rise in the company’s share price on January...

read more
UK Boosts Clinical Trials With Faster, Agile Regulation

UK Boosts Clinical Trials With Faster, Agile Regulation

Press Release: Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation  The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Five Ways AI Will Reshape Life Sciences in 2026

Five Ways AI Will Reshape Life Sciences in 2026

Why People, Process, and Purpose Matter Most Following a period of experimentation, life sciences is entering a pivotal new phase in AI adoption. The industry is shifting away from hype-driven pilots and toward proven, value-led applications that improve how therapies...

read more
Why Hormone Tracking will be a Key Health Trend for 2026

Why Hormone Tracking will be a Key Health Trend for 2026

Hormone health expert and bestselling author Dr Louise Newson explains why we'll all be tracking our hormones in 2026. The use of period tracking apps and menopause symptom tracker apps are at an all-time high. And it’s no wonder. These apps can be incredibly useful...

read more
OpenAI Accelerates Healthcare Strategy With ChatGPT Health

OpenAI Accelerates Healthcare Strategy With ChatGPT Health

OpenAI is making its most coordinated move into healthcare to date, positioning ChatGPT Health as a central interface for clinical, research, and operational use across the medical ecosystem. Rather than launching a single consumer-facing medical product, the company...

read more
The Lost World of Autism

The Lost World of Autism

Dhruv Shenai explores how females have been left behind in conversations on autism by discussing the history and lack of female representation within the field. Neuroscientist Gina Rippon has spent years challenging the male-centred bias in autism research. Her new...

read more
Why Life Sciences Can no Longer Rely on Traditional Media

Why Life Sciences Can no Longer Rely on Traditional Media

The life sciences industry is advancing at a speed that would have felt unimaginable just a few years ago. Artificial intelligence is shortening drug discovery timelines. Digital therapeutics are reshaping care delivery. Precision medicine is moving healthcare from...

read more

Further News

Fixing the Wrong Problem: How Healthcare Misdiagnoses its Workforce Crisis

The healthcare sector has a burnout problem it keeps trying to solve with the wrong tools. Across Australia and globally, rates of psychological distress, absenteeism and early career exit among healthcare workers have reached levels that can no longer be attributed...

Clinical Trials Roundup | 22 May 2026

Merck's sacituzumab tirumotecan meets both primary endpoints in the pivotal Phase 3 TroFuse-005 trial for advanced endometrial cancer, Relay Therapeutics reports the first clinical evidence of PI3Kα mutant-selective inhibition in PIK3CA-driven vascular anomalies in...

LillyPod Drug Discovery: Lilly’s NVIDIA Supercomputer Explained

Eli Lilly has switched on what it describes as the most powerful supercomputer ever owned and operated by a pharmaceutical company, and the implications for LillyPod drug discovery could reshape how medicines are found, tested, and delivered. Inaugurated in February...

Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...

Why Human-Led Billing is Making a Comeback in AI-Driven Healthcare System

For the past several years, the prevailing narrative in healthcare revenue cycle management has been straightforward: automate everything, reduce human touchpoints, and let artificial intelligence handle the complexity. The promise was compelling: faster claims...

Radiopharmaceuticals: The Cancer Treatment Reshaping Oncology

For decades, oncology ran on a handful of dominant modalities: surgery, chemotherapy, and radiotherapy, later joined by targeted therapies and immunotherapy. Radiopharmaceuticals have now entered that conversation as a serious contender. These drugs combine a...

Why Neurology Clinical Trials Need Purpose-Built AI

Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...

What the Veppanu Approval Means for ESR1 Breast Cancer

The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...

Burnout in the Helping Profession: Why Healthcare Keeps Getting it Wrong

Across the life sciences sector, a quiet crisis is unfolding. Researchers, clinicians, nurses, and social workers describe feeling trapped in a cycle with no exit: outwardly productive, inwardly depleted. Burnout is not a new phenomenon, but the life sciences...

Agentic AI in Drug Discovery: Why Big Pharma is All in

When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

China Drug Trials Now Outpace the US. Here is What That Means

China has overtaken the United States in the annual number of drug clinical trials. It is a sentence that would have seemed implausible a decade ago. Today, it is simply fact, and the implications for drug development, global pharma strategy, and geopolitical...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.